Phase1 finished, page-4

This is from the video posted on the website: [Geoffrey Kempler: So, we've just finished our phase one clinical trial, it was in about a little under 80 patients in multiple ascending doses, single ascending doses. The drug's proven to be very safe, so far.]
That is a pretty casual way to announce it. Maybe somebody needs some dementia treatment I would call that price sensitive, and the ASX requires an announcement to the market. He said it is complete and that there were no problems. All good news. I guess that means even the very high doses are good so far.